Volitinib

DRUG5 trials

Sponsors

Hutchison Medipharma Limited, Samsung Medical Center

Conditions

Advanced Gastric AdenocarcinomaFood EffectGastric CancerHealth SubjectsNon-Small Cell Lung CancerTumor

Phase 1

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

CompletedNCT01773018

Hutchison Medipharma LimitedTumor

Start: 2012-02-29End: 2016-05-31Updated: 2016-06-01

A Food Effect Phase I Study of the Volitinib in Healthy Subjects

CompletedNCT02017236

Hutchison Medipharma LimitedFood Effect, Health Subjects

Start: 2013-11-30End: 2014-06-30Updated: 2019-05-14

A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer

CompletedNCT02252913

Hutchison Medipharma LimitedGastric Cancer

Start: 2014-09-30End: 2015-12-31Updated: 2016-04-08

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

CompletedNCT02374645

Hutchison Medipharma LimitedNon-Small Cell Lung Cancer

Start: 2015-04-30End: 2018-09-14Updated: 2020-04-24

Phase 2

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

CompletedNCT02449551

Samsung Medical CenterAdvanced Gastric Adenocarcinoma

Start: 2016-02-10End: 2021-08-27Updated: 2022-06-15

Related Papers

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.

2020-10-1458 citations

Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.

Journal of Clinical Oncology2017-05-209 citations

Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.

Journal of Clinical Oncology2016-05-204 citations

cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).

Journal of Clinical Oncology2015-03-016 citations

First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.

Journal of Clinical Oncology2014-05-2015 citations